Skip to main content

Table 3 Clinical response and symptomatic remission outcomes in the long-term study among participants who completed dose optimization, by optimized dose (n=327)

From: Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

  LDX
30 mg/d (n=44) 50 mg/d (n=112) 70 mg/d (n=171) All Doses (n=327)
Clinical response, n (%) 42 (95.5) 107 (95.5) 164 (95.9) 313 (95.7a)
Symptomatic remission, n (%) 38 (86.4) 95 (84.8) 145 (84.8) 278 (85.0b)
  1. aSee Figure 4.
  2. bSee Figure 5.
  3. Abbreviation: LDX lisdexamfetamine dimesylate.